SCHEMBL16570837

SCHEMBL16570837

CNS(=O)(=O)c1cccc(Cn2ccc3cnc(Nc4ccc5c(c4)CCC(=O)N5)nc32)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 9/20 0.53
▸ PTK2 Q05397 4/20 0.53
▸ CDK1 P06493 2/20 0.53
▸ PTK2B Q14289 2/20 0.53
▸ CCNB1 P14635 1/20 0.53
▸ CDK7 P50613 1/20 0.53
▸ JAK3 P52333 2/20 0.52
▸ AURKA O14965 1/20 0.52
▸ DCLK1 O15075 1/20 0.52
▸ PDPK1 O15530 1/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ ROCK2 O75116 1/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ MAP4K4 O95819 1/20 0.52
▸ EGFR P00533 1/20 0.52
▸ NTRK1 P04629 1/20 0.52
▸ PRKCG P05129 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ LYN P07948 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571393 0.92 ULK1 (0.62) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570623 0.85 PTK2 (0.46) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570355 0.85 PTK2B (0.61) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570609 0.85 PTK2B (0.55) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570339 0.84 PTK2 (0.55) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570904 0.80 ULK1 (0.46) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570430 0.79 PTK2B (0.49) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570440 0.79 ULK1 (0.48) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16571159 0.78 PTK2 (0.56) ULK1PTK2CDK1PTK2BCCNB1
SCHEMBL16570750 0.77 PTK2 (0.66) ULK1PTK2CDK1PTK2BCDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN ULK1 769/4885PTK2 2/4885CDK1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback